ACTU (Actuate Therapeutics) Notes Receivable: $0.00 Mil (As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics Notes Receivable?

Actuate Therapeutics ACTU -14.29% 14 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Actuate Therapeutics Notes Receivable Related Terms

Actuate Therapeutics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Notes Receivable Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Actuate Therapeutics (ACTU) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Notes Receivable too high?
Actuate Therapeutics' current Notes Receivable is $0.00 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Notes Receivable compare to AURX and ESLA?
Actuate Therapeutics' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price